DC EKG with Joe Grogan

The Economics of Ozempic and Other Weight Loss Drugs

Episode 136.5 (“Prescription Refill” – A replay from the archives)

Original Air Date: May 2024

In this episode, Joe Grogan welcomes Ben Ippolito, Senior Fellow in Economic Policy Studies at the American Enterprise Institute, to discuss the rapidly evolving economics of GLP-1 weight loss drugs like Ozempic and Wegovy.

Ben explains the two main competitors in this market—Novo Nordisk's Ozempic and Wegovy versus Eli Lilly's Mounjaro and Zepbound. Revealing how insurance coverage decisions drive pharmaceutical marketing strategy.

The conversation reveals a critical irrationality in Medicare policy: the statutory prohibition on covering weight loss drugs despite their profound clinical and quality-of-life benefits. Yet these same drugs are covered for diabetes and cardiovascular risk reduction.

Ben explores the surprising economics of drug pricing through gross-to-net pricing—the massive gap between list prices and what insurers actually pay through rebates and discounts.

The episode examines critical implications of the Inflation Reduction Act's price negotiation provisions. Once Medicare negotiates Ozempic's price, that same price applies to all products using the same active ingredient. This creates cascading market effects: competitors must match those prices to remain on formularies, new entrants face lower pricing power even if clinically superior, and pharmaceutical companies may abandon promising programs due to regulatory uncertainty.

Ben argues Congress doesn't need to act immediately to expand Medicare coverage, but likely will within a few years.

Joe and Ben discuss unintended consequences of government price regulation, including effects on innovation and drug development pipelines. They explore how price controls announced before elections affect pharmaceutical strategy and development timelines.

Concluding with Ben's research on Medicare Advantage and why both Democrats and Republicans scrutinize this private alternative to traditional Medicare. With over 50 percent of seniors enrolled in Medicare Advantage plans, bipartisan interest in reform is reshaping healthcare policy conversations on Capitol Hill.

Key Topics

GLP-1 drugs, Ozempic, Wegovy, Mounjaro, Zepbound, weight loss medications, obesity treatment, Medicare coverage, drug pricing, Inflation Reduction Act, pharmaceutical competition, rebates, gross-to-net pricing, health economics, cardiovascular benefits, diabetes treatment, Medicare Advantage, healthcare policy, innovation incentives

Key Timestamps

00:00 Cold Open: "Turned Up to 11"

00:24 Welcome to DC EKG

00:46 Meet Ben Ippolito (AEI)

03:48 The GLP-1 Landscape: Ozempic, Wegovy, and the Field

05:04 One Drug, Two Names

06:45 Medicare's Weight-Loss Coverage Ban

07:21 Blockbusters and Big Effect Sizes

09:32 Why Isn't Congress Acting?

10:17 Why It Costs Less Than You Think

12:34 The Coverage Irrationality

14:05 Quality of Life as a Real Benefit

15:17 Beyond Weight: Cravings and Addiction

18:21 Devil's Advocate: Why Cover It At All?

19:48 Gross-to-Net and the Rebate Problem

22:41 Why Can't You Just Pay Cash?

25:43 The IRA and the Ozempic Price Cut

27:32 One Ingredient, One Price

30:10 Unintended Consequences in Part D

34:01 New Competitors and Killed Programs

38:03 What's Next: Medicare Advantage

42:04 Wrap-Up and Credits

About the Guest

(As of May 2024) Ben Ippolito is a Senior Fellow in Economic Policy Studies at the American Enterprise Institute. He holds a PhD and Master's degree in Economics from the University of Wisconsin-Madison and a Bachelor's degree in Mathematics and Economics from Emory University. Ben examines drug pricing policy, Medicare Advantage, and healthcare innovation economics with regular engagement with Congress.

Podcast: DC EKG with Joe Grogan

Guest: Ben Ippolito

Sponsor: Survivors for Solutions

Producer: Stay on Course Studios

Executive Producer: John CZ Czwartacki, DC EKG Podcast